Compass Pathways Eyes Rolling FDA Filing for COMP360, Preps TRD Launch Ahead of Q3 Data

Compass Pathways (NASDAQ:CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch ...

Compass Pathways Highlights Phase 3 COMP360 TRD Gains, 26-Week Durability and FDA Path at Conference

Executives from Compass Pathways (NASDAQ:CMPS) discussed recent Phase 3 results for its COMP360 psilocybin program in treatment-resistant depression (TRD), highlighting statistically significant ...
Psychology TodayOpinion

The Government Exhibits Caution About Psychedelics

Fast-tracked psychedelics hit a wall: why the FDA’s pause on psilocybin is an important check to ensure safety, rigor, and ...
Seeking Alpha

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

Research will take place in the UK, including at the newly opened Centre for Mental Health Research and Innovation in London, developed in partnership with South London and Maudsley NHS Foundation ...
Nasdaq

Is Compass Pathways Stock a Once-in-a-Lifetime Bargain?

Compass Pathways (NASDAQ: CMPS) is not your typical healthcare company. The London-based clinical-stage biopharma is developing therapies for various forms of depression that center around psilocybin, ...